% ============================================================================
% CONSTRAINT STORY: fda_component_efficacy_standard
% ============================================================================
% Version: 1.0 (Deferential Realism Core + Directionality + Boltzmann + Network)
% Logic: 6.0 (Indexed Tuple P,T,E,S + Sigmoid f(d) + Coupling + Purity + Network)
% Generated: 2024-02-29
% Status: [ACTIVE]
% ============================================================================

:- module(constraint_fda_component_efficacy_standard, []).

:- use_module(constraint_indexing).
:- use_module(domain_priors).
:- use_module(narrative_ontology).

% --- Constraint Identity Rule (DP-001: ε-Invariance) ---
% Each constraint story must have a single, stable base extractiveness (ε).
% If changing the observable used to evaluate this constraint would change ε,
% you are looking at two distinct constraints. Write separate .pl files for
% each, link them with affects_constraint/2, and document the relationship
% in both files' narrative context sections.
%
% The context tuple is CLOSED at arity 4: (P, T, E, S).
% Do not add measurement_basis, beneficiary/victim, or any other arguments.
% Linter Rule 23 enforces context/4.
%
% See: epsilon_invariance_principle.md

% --- Namespace Hooks (Required for loading) ---
:- multifile
    domain_priors:base_extractiveness/2,
    domain_priors:suppression_score/2,
    domain_priors:theater_ratio/2,
    domain_priors:requires_active_enforcement/1,
    narrative_ontology:has_sunset_clause/1,
    narrative_ontology:interval/3,
    narrative_ontology:measurement/5,
    narrative_ontology:constraint_metric/3,
    narrative_ontology:constraint_beneficiary/2,
    narrative_ontology:constraint_victim/2,
    narrative_ontology:constraint_claim/2,
    narrative_ontology:affects_constraint/2,
    narrative_ontology:coordination_type/2,
    constraint_indexing:constraint_classification/3,
    narrative_ontology:omega_variable/3,
    narrative_ontology:human_readable/2,
    narrative_ontology:topic_domain/2.

/* ==========================================================================
   1. NARRATIVE CONTEXT
   ========================================================================== */

/**
 * CONSTRAINT IDENTIFICATION
 *   constraint_id: fda_component_efficacy_standard
 *   human_readable: FDA's Component-Level Efficacy Standard for Combination Vaccines
 *   domain: technological/political
 *
 * SUMMARY:
 *   The FDA's component-level efficacy standard for combination vaccines aims
 *   to streamline vaccine development and improve public health outcomes by
 *   combining multiple vaccines into a single shot. However, this approach
 *   introduces trade-offs, as the efficacy of individual components may be
 *   compromised to facilitate combination. This constraint story explores the
 *   dynamics of this standard, analyzing its beneficiaries, victims, and
 *   potential risks from multiple perspectives.
 *
 * KEY AGENTS:
 *   - Vaccine Manufacturers: Primary beneficiary (institutional/arbitrage) – benefits from streamlined development and reduced costs.
 *   - FDA Regulatory Processes: Secondary beneficiary (institutional/constrained) – benefits from clear regulatory metrics and efficient approval processes.
 *   - Public Health Outcomes: Primary victim (powerless/trapped) – bears the risk of reduced overall protection and potential health crises.
 *   - Vulnerable Populations: Secondary victim (moderate/constrained) – constrained by increased susceptibility to disease and limited access to alternatives.
 *   - Analytical Observer: Objective analyst (analytical/analytical) – assesses trade-offs and potential risks.
 */

/* ==========================================================================
   2. BASE PROPERTIES (DOMAIN PRIORS)
   ========================================================================== */

% --- Numerical metrics ---
domain_priors:base_extractiveness(fda_component_efficacy_standard, 0.55).
domain_priors:suppression_score(fda_component_efficacy_standard, 0.4).
domain_priors:theater_ratio(fda_component_efficacy_standard, 0.2).

% --- Constraint metric facts (engine primary keys, must mirror domain_priors) ---
narrative_ontology:constraint_metric(fda_component_efficacy_standard, extractiveness, 0.55).
narrative_ontology:constraint_metric(fda_component_efficacy_standard, suppression_requirement, 0.4).
narrative_ontology:constraint_metric(fda_component_efficacy_standard, theater_ratio, 0.2).

% --- Constraint claim ---
narrative_ontology:constraint_claim(fda_component_efficacy_standard, tangled_rope).
narrative_ontology:human_readable(fda_component_efficacy_standard, "FDA's Component-Level Efficacy Standard for Combination Vaccines").
narrative_ontology:topic_domain(fda_component_efficacy_standard, "technological/political").

domain_priors:requires_active_enforcement(fda_component_efficacy_standard).

% --- Structural relationships ---
narrative_ontology:constraint_beneficiary(fda_component_efficacy_standard, vaccine_manufacturers).
narrative_ontology:constraint_beneficiary(fda_component_efficacy_standard, fda_regulatory_processes).
narrative_ontology:constraint_victim(fda_component_efficacy_standard, public_health_outcomes).
narrative_ontology:constraint_victim(fda_component_efficacy_standard, vulnerable_populations).

/* ==========================================================================
   3. INDEXED CLASSIFICATIONS (P, T, E, S)
   ========================================================================== */

% The public, particularly vulnerable populations, are trapped within the national healthcare system and are highly dependent on the efficacy and safety of vaccines. Inadequate component-level efficacy can lead to reduced overall protection and potential health crises, with no viable exit option.
constraint_indexing:constraint_classification(fda_component_efficacy_standard, snare,
    context(agent_power(powerless),
            time_horizon(generational),
            exit_options(trapped),
            spatial_scope(national))).

% Vulnerable populations (e.g., infants, immunocompromised individuals) are constrained by their increased susceptibility to infectious diseases and limited access to alternative preventative measures. While they benefit from the existence of vaccines, a lower efficacy standard extracts a higher risk from them. They have constrained, rather than trapped, exit options because individual physicians can advise on specific vaccines, but that advice is still within the overall framework.
constraint_indexing:constraint_classification(fda_component_efficacy_standard, tangled_rope,
    context(agent_power(moderate),
            time_horizon(generational),
            exit_options(constrained),
            spatial_scope(national))).

% Vaccine manufacturers benefit from a clear regulatory pathway and reduced development costs associated with combination vaccines. They have arbitrage exit options, as they can choose which components to combine and how to market the resulting product, allowing them to optimize profitability within the regulatory framework.
constraint_indexing:constraint_classification(fda_component_efficacy_standard, rope,
    context(agent_power(institutional),
            time_horizon(biographical),
            exit_options(arbitrage),
            spatial_scope(national))).

% The FDA as an institution benefits from having a defined, enforceable efficacy standard. This standard allows for regulatory processes to continue and provides clear metrics for approval. The agency can't 'exit' but can shift resources or re-prioritize which is a constrained exit option.
constraint_indexing:constraint_classification(fda_component_efficacy_standard, rope,
    context(agent_power(institutional),
            time_horizon(civilizational),
            exit_options(constrained),
            spatial_scope(national))).

% From an analytical perspective, the component-level efficacy standard represents a tangled rope. It facilitates the development and distribution of combination vaccines (coordination), but also introduces potential compromises in individual component efficacy (extraction), making it a hybrid constraint with both benefits and drawbacks.
constraint_indexing:constraint_classification(fda_component_efficacy_standard, tangled_rope,
    context(agent_power(analytical),
            time_horizon(civilizational),
            exit_options(analytical),
            spatial_scope(global))).

/* ==========================================================================
   4. VALIDATION TESTS
   ========================================================================== */

:- begin_tests(fda_component_efficacy_standard_tests).

test(perspectival_gap) :-
    constraint_indexing:constraint_classification(fda_component_efficacy_standard, TypePowerless, context(agent_power(powerless), _, _, _)),
    constraint_indexing:constraint_classification(fda_component_efficacy_standard, TypeOther, context(agent_power(moderate), _, _, _)),
    TypePowerless \= TypeOther.

test(extraction_signature) :-
    domain_priors:base_extractiveness(fda_component_efficacy_standard, E),
    E >= 0.46. % Ensures high-extraction Snare/Tangled territory.

:- end_tests(fda_component_efficacy_standard_tests).

/* ==========================================================================
   5. GENERATIVE COMMENTARY
   ========================================================================== */

/**
 * LOGIC RATIONALE:
 *   Extractiveness (0.55): Moderate-high. The potential compromise in individual component efficacy extracts a risk from public health outcomes and vulnerable populations. Suppression (0.40): Moderate. The standard does suppress the development of single-component vaccines that might offer higher efficacy, or create barriers for novel vaccine technologies that don't easily fit within the combination framework. Theater ratio (0.20): Low. The FDA requires clinical trials to demonstrate the efficacy of combination vaccines, so performative aspects are minimal.
 *
 * PERSPECTIVAL GAP:
 *   The perspectival gap is evident between vaccine manufacturers, who see a streamlined regulatory pathway (Rope), and public health, which bears the risk of reduced protection (Snare). Vulnerable populations experience a tangled rope, as they benefit from vaccine availability but face a higher risk of reduced efficacy. The analytical observer sees the broader trade-offs inherent in the standard (Tangled Rope).
 *
 * DIRECTIONALITY LOGIC:
 *   Vaccine manufacturers benefit from streamlined processes and profitability. The FDA benefits from maintaining a clear regulatory framework. Public health outcomes and vulnerable populations bear the risk of reduced efficacy and potential health crises. The analytical observer sees the overall trade-offs.
 *
 * MANDATROPHY ANALYSIS:
 *   The mandatrophy is resolved by recognizing that the component-level efficacy standard is a tangled rope: a hybrid constraint with both coordination (streamlining vaccine development) and extraction (potential compromise in efficacy). It prevents mislabeling coordination as pure extraction (or vice versa) by acknowledging the inherent trade-offs and considering multiple perspectives.
 */

/* ==========================================================================
   6. OMEGA VARIABLES (Ω) - IRREDUCIBLE UNCERTAINTIES
   ========================================================================== */

omega_variable(
    efficacy_threshold_vs_adoption,
    'What is the optimal efficacy threshold for individual vaccine components that maximizes overall public health benefits, considering trade-offs between efficacy and adoption rates?',
    'Epidemiological modeling, clinical trials, and real-world effectiveness studies.',
    'Higher efficacy standards might lead to reduced vaccine availability and higher costs, affecting adoption rates, while lower standards may compromise public health protection.',
    confidence_without_resolution(medium)
).

narrative_ontology:omega_variable(efficacy_threshold_vs_adoption, empirical, 'Determining the optimal efficacy threshold for vaccine components.').

omega_variable(
    immunological_interference_risk,
    'What is the risk of immunological interference between different vaccine components in combination vaccines, and how can this interference be mitigated?',
    'Immunogenicity studies, clinical trials, and post-market surveillance.',
    'Immunological interference may reduce the efficacy of individual components, impacting overall vaccine effectiveness and potentially increasing disease incidence.',
    confidence_without_resolution(medium)
).

narrative_ontology:omega_variable(immunological_interference_risk, empirical, 'Assessing the risk of immunological interference in combination vaccines.').


/* ==========================================================================
   7. INTEGRATION HOOKS
   ========================================================================== */

narrative_ontology:interval(fda_component_efficacy_standard, 0, 10).

/* ==========================================================================
   8. TEMPORAL MEASUREMENTS (LIFECYCLE DRIFT DATA)
   ========================================================================== */

% Theater ratio over time
narrative_ontology:measurement(fda__tr_t0, fda_component_efficacy_standard, theater_ratio, 0, 0.1).
narrative_ontology:measurement(fda__tr_t5, fda_component_efficacy_standard, theater_ratio, 5, 0.15).
narrative_ontology:measurement(fda__tr_t10, fda_component_efficacy_standard, theater_ratio, 10, 0.2).

% Extraction over time
narrative_ontology:measurement(fda__be_t0, fda_component_efficacy_standard, base_extractiveness, 0, 0.4).
narrative_ontology:measurement(fda__be_t5, fda_component_efficacy_standard, base_extractiveness, 5, 0.48).
narrative_ontology:measurement(fda__be_t10, fda_component_efficacy_standard, base_extractiveness, 10, 0.55).


/* ==========================================================================
   9. BOLTZMANN & NETWORK DATA
   ========================================================================== */

narrative_ontology:coordination_type(fda_component_efficacy_standard, resource_allocation).
narrative_ontology:affects_constraint(fda_component_efficacy_standard, vaccine_access_inequality).
narrative_ontology:affects_constraint(fda_component_efficacy_standard, anti_vaccine_sentiment).

/* ==========================================================================
   10. DIRECTIONALITY OVERRIDES (v6.0, OPTIONAL)
   ========================================================================== */

/* ==========================================================================
   END OF CONSTRAINT STORY
   ========================================================================== */
